Literature DB >> 12019149

Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma.

Hiroaki Kajiyama1, Fumitaka Kikkawa, Takahiro Suzuki, Kiyosumi Shibata, Kazuhiko Ino, Shigehiko Mizutani.   

Abstract

Dipeptidyl peptidase IV (DPPIV) is a multifunctional cell surface aminopeptidase with ubiquitous expression. Recent studies have suggested that DPPIV plays an important role in tumor progression in several human malignancies. In the present study, we investigated the correlation between DPPIV expression and progressive potential in ovarian carcinoma. We demonstrated that ovarian carcinoma cell lines with higher DPPIV expression were less invasive. Furthermore, DPPIV overexpression in SKOV3 cells, derived from serous cystadenocarcinoma, with little DPPIV expression induced a dramatic change in cellular morphology and a significant decrease in the abilities of both migration and invasion. In addition, we have also shown that nude mice inoculated with DPPIV-transfected SKOV3 cells showed significantly less peritoneal dissemination and longer survival time than those receiving the parental or vector-only transfected cells (mean survival time, 64.9 +/- 4.7, 35.7 +/- 2.8, and 36.6 +/- 1.8 days, respectively). This evidence implies that DPPIV may functionally suppress peritoneal dissemination in ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019149

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  3D-QSAR studies of Dipeptidyl peptidase IV inhibitors using a docking based alignment.

Authors:  Raghuvir R S Pissurlenkar; Mushtaque S Shaikh; Evans C Coutinho
Journal:  J Mol Model       Date:  2007-08-04       Impact factor: 1.810

2.  Possible involvement of TWIST in enhanced peritoneal metastasis of epithelial ovarian carcinoma.

Authors:  Mikio Terauchi; Hiroaki Kajiyama; Mamoru Yamashita; Mikihiko Kato; Hirohisa Tsukamoto; Tomokazu Umezu; Satoyo Hosono; Eiko Yamamoto; Kiyosumi Shibata; Kazuhiko Ino; Akihiro Nawa; Tetsuro Nagasaka; Fumitaka Kikkawa
Journal:  Clin Exp Metastasis       Date:  2007-05-09       Impact factor: 5.150

3.  Expression levels of seprase/FAPα and DPPIV/CD26 in epithelial ovarian carcinoma.

Authors:  Mengzhen Zhang; Liwei Xu; Xiaoling Wang; Beibei Sun; Juan Ding
Journal:  Oncol Lett       Date:  2015-04-27       Impact factor: 2.967

Review 4.  Proteases in cutaneous malignant melanoma: relevance as biomarker and therapeutic target.

Authors:  Eleonore Fröhlich
Journal:  Cell Mol Life Sci       Date:  2010-08-05       Impact factor: 9.261

5.  KiSS1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase C alpha.

Authors:  Ying Jiang; Michael Berk; Lisam Shanjukumar Singh; Haiyan Tan; Lihong Yin; C Thomas Powell; Yan Xu
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

6.  Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis.

Authors:  Hal E Broxmeyer; Jonathan Hoggatt; Heather A O'Leary; Charlie Mantel; Brahmananda R Chitteti; Scott Cooper; Steven Messina-Graham; Giao Hangoc; Sherif Farag; Sara L Rohrabaugh; Xuan Ou; Jennifer Speth; Louis M Pelus; Edward F Srour; Timothy B Campbell
Journal:  Nat Med       Date:  2012-11-18       Impact factor: 53.440

7.  Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old.

Authors:  Dilek Colak; Muhammad A Chishti; Al-Bandary Al-Bakheet; Ahmed Al-Qahtani; Mohamed M Shoukri; Malcolm H Goyns; Pinar T Ozand; John Quackenbush; Ben H Park; Namik Kaya
Journal:  Mol Cancer       Date:  2010-06-12       Impact factor: 27.401

8.  The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism.

Authors:  Michael Engel; Torsten Hoffmann; Leona Wagner; Michael Wermann; Ulrich Heiser; Reiner Kiefersauer; Robert Huber; Wolfram Bode; Hans-Ulrich Demuth; Hans Brandstetter
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-10       Impact factor: 11.205

Review 9.  DPPIV/CD26: a tumor suppressor or a marker of malignancy?

Authors:  Aline Beckenkamp; Samuel Davies; Júlia Biz Willig; Andréia Buffon
Journal:  Tumour Biol       Date:  2016-03-04

10.  CD26 expression on T cell lines increases SDF-1-alpha-mediated invasion.

Authors:  P A Havre; M Abe; Y Urasaki; K Ohnuma; C Morimoto; N H Dang
Journal:  Br J Cancer       Date:  2009-08-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.